Zobrazeno 1 - 10
of 193
pro vyhledávání: '"Tiffany A Traina"'
Autor:
Kelly E. McCann, Shari B. Goldfarb, Tiffany A. Traina, Meredith M. Regan, Neelima Vidula, Virginia Kaklamani
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-5 (2024)
Abstract Use of gonadotropin-releasing hormone (GnRH) agonists has been widely adopted to provide reversible ovarian function suppression for pre-menopausal breast cancer patients who are also receiving aromatase inhibitor or tamoxifen therapy based
Externí odkaz:
https://doaj.org/article/5053e0062ab54721911780e954ef0130
Autor:
Joseph J. Connolly, Laura M. Spring, Alphonse G. Taghian, Michele Gadd, Laura Warren, Ana C. Garrido-Castro, Tari King, Elizabeth A. Mittendorf, Jose P. Leone, Dana L. Casey, Lisa Carey, Tiffany A. Traina, Yara Abdou, Atif Khan, George Plitas, Jean Wright, Cesar Augusto Santa-Maria, Lisa Jacobs, Rachel Blitzblau, E Shelley Hwang, Carey Anders, Ian Krop, Antonio C. Wolff, Alastair M. Thompson, Elyssa Denault, Gaorav Gupta, Alice Ho
Publikováno v:
Cancer Research. 83:OT3-15
Background: The introduction of immune checkpoint inhibitors (ICI) to standard neoadjuvant chemotherapy regimens has been shown to significantly improve outcomes in patients with triple negative breast cancer and is being investigated for high-risk h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fe29f98c579ab5f1dba096ba9decb89
https://doi.org/10.1158/1538-7445.sabcs22-ot3-15-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-15-01
Publikováno v:
Cancer Research. 83:OT2-17
Background: The prognosis for advanced/metastatic triple negative breast cancer (TNBC) remains poor and novel therapeutic strategies are urgently needed to improve outcomes. Insulin resistance and obesity contribute to cancer progression and are inde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1833d723edd8e6d27906f6a9c8fc6740
https://doi.org/10.1158/1538-7445.sabcs22-ot2-17-02
https://doi.org/10.1158/1538-7445.sabcs22-ot2-17-02
Autor:
Heather A. Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana Abramson, Ashka Patel, Ju Cheng, Adam M. Brufsky, Justin Rhoades, Jeremy Force, Ruolin Liu, Tiffany A. Traina, Lisa Carey, Mothaffar Rimawi, Ahmed Elkhanany, Vered Stearns, Jennifer M. Specht, Harold Burstein, Antonio C. Wolff, Eric Winer, Nabihah Tayob, Ian Krop, Todd Golub, Erica L. Mayer, Viktor Adalsteinsson
Publikováno v:
Cancer Research. 83:PD11-06
Background. Patients (pts) with early triple negative breast cancer (eTNBC) are at increased risk of breast cancer recurrence and death. Recent studies have focused on escalation of therapy, with current treatment standard of at least five drugs –
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c514faa25bf89ae79cd6e545d5bd35c9
https://doi.org/10.1158/1538-7445.sabcs22-pd11-06
https://doi.org/10.1158/1538-7445.sabcs22-pd11-06
Publikováno v:
Cancer Research. 83:P6-08
Background: Providers and patients alike are unaware of the racial disparities that exist in triple-negative breast cancer (TNBC), which occurs at twice the rate in women of the African Diaspora (WAD) compared to White American women. WAD tend to be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cec29642f731562907c6e3393e695272
https://doi.org/10.1158/1538-7445.sabcs22-p6-08-06
https://doi.org/10.1158/1538-7445.sabcs22-p6-08-06
Autor:
Rebecca Dent, David W. Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A. Traina, Petra Vuković, Darlington Mapiye, Micah Maxwell, Peter Schmid, Javier Cortés
Publikováno v:
Cancer Research. 83:OT1-03
Introduction: Despite recent treatment advances, the prognosis for patients diagnosed with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) remains poor. Single-agent chemotherapy has been the mainstay of treatment for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d460c2421b61c41a1ffd56ee0aef42b5
https://doi.org/10.1158/1538-7445.sabcs22-ot1-03-05
https://doi.org/10.1158/1538-7445.sabcs22-ot1-03-05
Autor:
Kerry Mullaney, Donna C. Ferguson, Tiffany A. Traina, Marc Ladanyi, Timothy Ky. Tay, Ryma Benayed, Edi Brogi, Maria E. Arcila, Douglas A. Mata, Sarat Chandarlapaty, Ayca Gucalp, Timothy M. D'Alfonso, Dara S. Ross
Publikováno v:
Modern Pathology. 35:396-402
Androgen receptor (AR) inhibitor therapy is a developing treatment for AR-positive breast cancer (BC) with ongoing clinical trials. AR splice variant-7 (AR-V7) is a truncated variant of AR that leads to AR inhibitor therapy resistance in prostate can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c868a70e90fa921de935fb2c86906aa3
https://doi.org/10.1038/s41379-021-00924-5
https://doi.org/10.1038/s41379-021-00924-5
Autor:
Elaine M Walsh, Ayca Gucalp, Sujata Patil, Marcia Edelweiss, Dara S Ross, Pedram Razavi, Shanu Modi, Neil M Iyengar, Rachel Sanford, Tiffany Troso-Sandoval, Mila Gorsky, Jackie Bromberg, Pamela Drullinsky, Diana Lake, Serena Wong, Patricia DeFusco, Nicholas Lamparella, Ranja Gupta, Tasmila Tabassum, Leigh Ann Boyle, Artavazd Arumov, Tiffany A Traina
Publikováno v:
Cancer Research. 82:P1-14
Background: Chemotherapy remains the mainstay of treatment for early-stage triple negative breast cancer (TNBC), yet targetable drivers of interest are under investigation. A subset of TNBCs express the androgen receptor (AR) and exhibit androgen-dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c13cb51455eb77d7eedf06d84d46453
https://doi.org/10.1158/1538-7445.sabcs21-p1-14-03
https://doi.org/10.1158/1538-7445.sabcs21-p1-14-03
Autor:
David B Page, Krystle L Collins, Brie Chun, Zhaoyu Sun, William L Redmond, Maritza Martel, Yaping Wu, Nicole Moxon, Staci L Mellinger, Walter J Urba, Tiffany A Traina, Ayca Gucalp
Publikováno v:
Cancer Research. 82:OT1-18
Background: The addition of anti-programmed death 1/ligand 1 (anti-PD-1/L1) improves progression-free survival when combined with chemotherapy in PD-L1-positive triple-negative MBC. However, novel combination therapies are needed to improve efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9b938b2e53e4389e39fe14140954f1c
https://doi.org/10.1158/1538-7445.sabcs21-ot1-18-04
https://doi.org/10.1158/1538-7445.sabcs21-ot1-18-04
Autor:
Tiffany A. Traina, Clifford A. Hudis, Kimberly N. Feigin, Sujata Patil, Dilip D. Giri, Arooj Akhtar, Joseph M. Gonzalez, Lamia F. Momen, Mary Ellen Moynahan, Michael Danso, Ashley S. Doane, Vered Stearns, Andres Forero, Lisle Nabell, Hope Rugo, Kimberly Blackwell, Lisa A. Carey, Minetta C. Liu, James N. Ingle, Steven J. Isakoff, Sara Tolaney, Ayca Gucalp
Supplementary Figure 1 - PDF file 44K, Supplementary Figure 1A-D. Median hormone levels at baseline, C2 and EOS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afea8e831c45ba47eb7bd70f2c87d692
https://doi.org/10.1158/1078-0432.22449011
https://doi.org/10.1158/1078-0432.22449011
